中新集團(601512.SH):擬出資不超1.1億元參投蘇州華業致遠三號股權投資合夥企業
格隆匯3月29日丨中新集團(601512.SH)公佈,公司擬作為有限合夥人以自有資金參與投資蘇州華業致遠三號股權投資合夥企業(有限合夥)(簡稱“標的基金”),重點關注新一代信息技術、新能源、新材料等領域的投資機會。標的基金已於2021年12月29日完成工商註冊,於2022年2月16日完成中國證券投資基金業協會備案(基金編號:STN459)。標的基金目標規模約15億元,最終以實際募集情況為準。公司擬認繳出資不超過1.1億元,且佔比不超過最終基金認繳總額的10%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.